抄録
Six patients with multiple myeloma and 2 patients with primary macroglobulinemia were treated with a combination chemotherapy, consisting of vincristine, cyclophosphamide, procarbazine, ACNU and prednisolone (VENAP therapy).
Four of 6 patients with myeloma had become resistant to melphalan and/or cyclophosphamide, and 2 macroglobulinemia patients had not responded to chlorambucil and melphalan, and melphalan respectively.
A partial response was obtained in 5 of 5 evaluable myeloma cases, 4 of which had not responded to prior therapy.
On the other hand, 2 macroglobulinemia cases were judged as stable, however the amount of M-protein decreased below 50% of that at diagnosis in one case.
Results support the value of combination chemotherapy with VENAP for remission induction in patients with refractory multiple myeloma and allied disease. This therapy may be tried as an initial induction therapy for the “B-lymphocytes” malignancies.
